Search

Your search keyword '"Buzón, Luis"' showing total 18 results
Start Over Author "Buzón, Luis"
18 results on '"Buzón, Luis"'

1. Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers

Author

Julia del Amo, Polo, Rosa, Moreno, Santiago, Berenguer, Juan, Martínez, Esteban, Hernán, Miguel, Martínez de Salazar, Pablo, García de Albéniz, Xabier, García-Albéniz, Xabier, Terán, Carolina, Morales, Miguel, Rial-Crestelo, David, Garcinuño, M. Angeles, García del Toro, Miguel, Hita, César, Gómez-Sirvent, Juan Luis, Buzón, Luis, Díaz de Santiago, Alberto, Arellano, Jose Pérez, Sanz, Jesus, Bachiller, Pablo, Alfaro, Elisa Martínez, Díaz-Brito, Vicente, Masiá, Mar, Hernández-Torres, Alicia, Guerra, Jose M., Santos, Jesús, Arazo, Piedad, Muñoz, Leopoldo, Arribas, Jose Ramon, Hernán, Miguel A., and Del Amo, Julia

Published
2023
Full Text
View/download PDF

2. COVID-19 anosmia and gustatory symptoms as a prognosis factor: a subanalysis of the HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) registry

Author

Porta-Etessam, Jesús, Núñez-Gil, Iván J., González García, Nuria, Fernandez-Perez, Cristina, Viana-Llamas, María C., Eid, Charbel Maroun, Romero, Rodolfo, Molina, María, Uribarri, Aitor, Becerra-Muñoz, Victor Manuel, Aguado, Marcos García, Huang, Jia, Rondano, Elisa, Cerrato, Enrico, Alfonso, Emilio, Mejía, Alex Fernando Castro, Marin, Francisco, Roubin, Sergio Raposeiras, Pepe, Martino, Feltes, Gisela, Maté, Paloma, Cortese, Bernardo, Buzón, Luis, Mendez, Jorge Játiva, and Estrada, Vicente

Published
2021
Full Text
View/download PDF

3. Clinical presentation, therapeutic approach, and outcome of young patients admitted for COVID-19, with respect to the elderly counterpart

Author

Pepe, Martino, Maroun-Eid, Charbel, Romero, Rodolfo, Arroyo-Espliguero, Ramón, Fernàndez-Rozas, Inmaculada, Aparisi, Alvaro, Becerra-Muñoz, Víctor Manuel, Garcìa Aguado, Marcos, Brindicci, Gaetano, Huang, Jia, Alfonso-Rodríguez, Emilio, Castro-Mejía, Alex Fernando, Favretto, Serena, Cerrato, Enrico, Albiol, Paloma, Raposeiras-Roubin, Sergio, Vedia, Oscar, Feltes Guzmãn, Gisela, Carrero-Fernández, Ana, Perez Cimarra, Clara, Buzón, Luis, Jativa Mendez, Jorge Luis, Abumayyaleh, Mohammad, Corbi-Pascual, Miguel, Macaya, Carlos, Estrada, Vicente, Nestola, Palma Luisa, Biondi-Zoccai, Giuseppe, and Núñez-Gil, Iván J.

Published
2021
Full Text
View/download PDF

4. Real-life data of immune recovery using bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV. Results at 48–96 weeks of RETROBIC Study

Author

Troya, Jesús, primary, Pousada, Guillermo, additional, Micán, Rafael, additional, Galera, Carlos, additional, Sanz, José, additional, de los Santos, Ignacio, additional, Dueñas, Carlos, additional, Cabello, Noemí, additional, Martín, Cristina, additional, Galindo, María Josefa, additional, Garcinuño, María Ángeles, additional, Pedrero-Tomé, Roberto, additional, and Buzón, Luis, additional

Published
2024
Full Text
View/download PDF

5. 1571. BIC/FTC/TAF in Virologically Suppressed PLWHIV: 48-96 weeks RETROBIC Multicenter Cohort study results.

Author

Estévez, Samuel, primary, Buzón, Luis, additional, Pousada, Guillermo, additional, Tomé, Roberto Pedrero, additional, Galera, Carlos, additional, Sanz, Jose, additional, Santos, Ignacio, additional, Dueñas, Carlos, additional, Cabello, Noemí, additional, Martín, Cristina, additional, Galindo, María José, additional, Garcinuño, María Ángeles, additional, Hernández, Cristina, additional, Lebón, Gabriela, additional, Fernández, Beatriz, additional, and Troya, Jesús, additional

Published
2023
Full Text
View/download PDF

7. Predict the Effects of Dolutegravir (DTG) Plus Lamivudine (3TC) on Immunological Responses in People Living with HIV (PLWHIV)

Author

Troya,Jesús, Pedrero Tomé, Roberto, Buzón, Luis, Dueñas, Carlos, Troya,Jesús, Pedrero Tomé, Roberto, Buzón, Luis, and Dueñas, Carlos

Abstract

Background: Immune recovery in people living with HIV (PLWHIV) is a residual aspect of antiretroviral treatment (ART) in most patients, but in a non-negligible proportion of them, the CD4+ lymphocytes count, or CD4/CD8 ratio remains suboptimal. Methods: We performed a model of the immune response after 24 weeks of switching to a 2DR with DTG plus 3TC in a retrospective multicenter cohort of undetectable and experienced patients using significant predictor variables associated with the parameters or situations defined as success and failure. Clinical variables studied were CD4+ and CD8+ lymphocyte count, percentage of CD4, and CD4/CD8 ratio. These parameters were assessed at baseline and 24 weeks after the switch. Based on the evolution of each variable, four categories of immune response and four categories of non-immune response were defined. Immune response was defined as CD4+ count > 500 cells/mm3, %CD4 > 30%, CD8+ count < 1000 cells/mm3 and CD4/CD8 ratio ≥ 0.9. Non-response is just the opposite. Results: In our different models of immunological response, the presence of stage of AIDS (p = 0.035, p = 0.065) and current age over 50 years (p = 0.045) are postulated as statistically significative limiting factors in achieving an improvement in CD4, %CD4, CD8, and CD4/CD8 ratio. Late HIV diagnosis (p = 0.156), without statistical significance, enhanced late the previous variables. In contrast, conditions where patients start with CD4 > 500 cells/mm3 (p = 0.054); CD4 > 30% (p = 0.054, p = 0.084); CD8 < 1000 cells/mm3 (p = 0.018), and CD4/CD8 ≥ 0.9 (p = 0.013, p = 0.09) are detected as stimulating or conducive to DTG plus 3TC treatment success. Conclusion: These models represent a proof of concept that could become a valuable tool for clinicians to predict the effects of DTG plus 3TC on immunological responses prior to the switch in undetectable pre-treated PLWHIV with immune dysfunction. The main predictors for immunological failure were late HIV diagnosis, stage of A, Depto. de Biodiversidad, Ecología y Evolución, Fac. de Medicina, Fac. de Ciencias Biológicas, TRUE, pub, Descuento UCM

Published
2023

8. Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV

Author

Dueñas-Gutiérrez, Carlos, primary, Buzón, Luis, additional, Pedrero-Tomé, Roberto, additional, Iribarren, José A., additional, De los Santos, Ignacio, additional, De la Fuente, Sara, additional, Pousada, Guillermo, additional, Moran, Miguel Angel, additional, Moreno, Estela, additional, Ferreira, Eva, additional, Gómez, Julia, additional, and Troya, Jesús, additional

Published
2023
Full Text
View/download PDF

9. Predict the Effects of Dolutegravir (DTG) Plus Lamivudine (3TC) on Immunological Responses in People Living with HIV (PLWHIV)

Author

Troya, Jesús, Pedrero-Tomé, Roberto, Buzón, Luis, Dueñas, Carlos, and Group, on behalf of the SPADE Study Group on behalf of the SPADE Study

Subjects
2DR, HIV, General Medicine, lamivudine, immune recovery, dolutegravir, nomograms
Abstract

Background: Immune recovery in people living with HIV (PLWHIV) is a residual aspect of antiretroviral treatment (ART) in most patients, but in a non-negligible proportion of them, the CD4+ lymphocytes count, or CD4/CD8 ratio remains suboptimal. Methods: We performed a model of the immune response after 24 weeks of switching to a 2DR with DTG plus 3TC in a retrospective multicenter cohort of undetectable and experienced patients using significant predictor variables associated with the parameters or situations defined as success and failure. Clinical variables studied were CD4+ and CD8+ lymphocyte count, percentage of CD4, and CD4/CD8 ratio. These parameters were assessed at baseline and 24 weeks after the switch. Based on the evolution of each variable, four categories of immune response and four categories of non-immune response were defined. Immune response was defined as CD4+ count > 500 cells/mm3, %CD4 > 30%, CD8+ count < 1000 cells/mm3 and CD4/CD8 ratio ≥ 0.9. Non-response is just the opposite. Results: In our different models of immunological response, the presence of stage of AIDS (p = 0.035, p = 0.065) and current age over 50 years (p = 0.045) are postulated as statistically significative limiting factors in achieving an improvement in CD4, %CD4, CD8, and CD4/CD8 ratio. Late HIV diagnosis (p = 0.156), without statistical significance, enhanced late the previous variables. In contrast, conditions where patients start with CD4 > 500 cells/mm3 (p = 0.054); CD4 > 30% (p = 0.054, p = 0.084); CD8 < 1000 cells/mm3 (p = 0.018), and CD4/CD8 ≥ 0.9 (p = 0.013, p = 0.09) are detected as stimulating or conducive to DTG plus 3TC treatment success. Conclusion: These models represent a proof of concept that could become a valuable tool for clinicians to predict the effects of DTG plus 3TC on immunological responses prior to the switch in undetectable pre-treated PLWHIV with immune dysfunction. The main predictors for immunological failure were late HIV diagnosis, stage of AIDS, and current age over 50 years. In contrast, starting with a normalized immune status was detected as stimulating or conducive to DTG plus 3TC treatment success.

Published
2023
Full Text
View/download PDF

10. Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic

Author

Buzón, Luis, primary, Dueñas, Carlos, additional, Pedrero, Roberto, additional, Iribarren, Jose, additional, de los Santos, Ignacio, additional, Díaz de Santiago, Alberto, additional, Morán, Miguel, additional, Pousada, Guillermo, additional, Moreno, Estela, additional, Ferreira, Eva, additional, Iglesias, Alicia, additional, Martín, Cristina, additional, Gómez, Julia, additional, Rodríguez, Laura, additional, Egido, Miguel, additional, Sepulveda, María-Antonia, additional, and Troya, Jesús, additional

Published
2023
Full Text
View/download PDF

12. Dolutegravir plus rilpivirine: benefits beyond viral suppression

Author

Troya, Jesús, primary, Dueñas, Carlos, additional, Irazola, Idoia, additional, de los Santos, Ignacio, additional, de la Fuente, Sara, additional, Gil, Desiré, additional, Hernández, Cristina, additional, Galindo, María José, additional, Gómez, Julia, additional, Delgado, Elisabeth, additional, Moreno-García, Estela, additional, Pousada, Guillermo, additional, Aldámiz, Teresa, additional, Iribarren, Jose Antonio, additional, Guerra, José Manuel, additional, Morán, Miguel Ángel, additional, Galera, Carlos, additional, De La Fuente, Javier, additional, Peláez, Ana, additional, Cervero, Miguel, additional, Garcinuño, María, additional, Montero, Marta, additional, Ceballos, Francisco, additional, and Buzón, Luis, additional

Published
2022
Full Text
View/download PDF

13. Hydroxychloroquine and Mortality in SARS-Cov-2 Infection; The HOPE- Covid-19 Registry.

Author

Núñez-Gil, Iván J., primary, Ayerbe, Luis, additional, Fernandez-Pérez, Cristina, additional, Estrada, Vicente, additional, Eid, Charbel Maroun, additional, Arroyo-Espliguero, Ramón, additional, Romero, Rodolfo, additional, Becerra-Muñoz, Víctor Manuel, additional, Uribarri, Aitor, additional, Feltes, Gisela, additional, Trabattoni, Daniela, additional, Molina, María, additional, Aguado, Marcos García, additional, Pepe, Martino, additional, Cerrato, Enrico, additional, Huang, Jia, additional, Astrua, Thamar Capel, additional, Alfonso, Emilio, additional, Castro-Mejía, Alex F., additional, Raposeiras-Roubin, Sergio, additional, Buzón, Luis, additional, Paeres, Carolina Espejo, additional, Mulet, Alba, additional, Lal-Trehan, Nisha, additional, Garcia-Vazquez, Elisa, additional, Fabregat-Andres, Oscar, additional, Akin, Ibrahim, additional, D´Ascenzo, Fabrizio, additional, Gomez-Rosado, Paula, additional, Ugo, Fabrizio, additional, Fernández-Ortiz, Antonio, additional, and Macaya, Carlos, additional

Published
2022
Full Text
View/download PDF

14. Anticoagulation Therapy in Patients With Coronavirus Disease 2019: Results From a Multicenter International Prospective Registry (Health Outcome Predictive Evaluation for Corona Virus Disease 2019 [HOPE-COVID19])

Author

Santoro, Francesco, primary, Núñez-Gil, Ivan J., additional, Viana-Llamas, María C., additional, Maroun Eid, Charbel, additional, Romero, Rodolfo, additional, Fernández Rozas, Inmaculada, additional, Aparisi, Alvaro, additional, Becerra-Muñoz, Victor Manuel, additional, García Aguado, Marcos, additional, Huang, Jia, additional, Maltese, Ludovica, additional, Cerrato, Enrico, additional, Alfonso-Rodriguez, Emilio, additional, Castro Mejía, Alex Fernando, additional, Marin, Francisco, additional, Raposeiras Roubin, Sergio, additional, Pepe, Martino, additional, Moreno Munguia, Victor H., additional, Feltes, Gisela, additional, Navas, Jesus Varas, additional, Cortese, Bernardo, additional, Buzón, Luis, additional, Liebetrau, Cristoph, additional, Ramos-Martinez, Raquel, additional, Fernandez-Ortiz, Antonio, additional, Estrada, Vicente, additional, and Brunetti, Natale Daniele, additional

Published
2021
Full Text
View/download PDF

15. Prognostic Impact of Hyponatremia and Hypernatremia in COVID-19 Pneumonia. A HOPE-COVID-19 (Health Outcome Predictive Evaluation for COVID-19) Registry Analysis.

Author

Ruiz-Sánchez, Jorge Gabriel, Núñez-Gil, Ivan J., Cuesta, Martin, Rubio, Miguel A., Maroun-Eid, Charbel, Arroyo-Espliguero, Ramón, Romero, Rodolfo, Becerra-Muñoz, Victor Manuel, Uribarri, Aitor, Feltes, Gisela, Trabattoni, Daniela, Molina, María, García Aguado, Marcos, Pepe, Martino, Cerrato, Enrico, Alfonso, Emilio, Castro Mejía, Alex Fernando, Roubin, Sergio Raposeiras, Buzón, Luis, and Bondia, Elvira

Subjects
HEALTH outcome assessment, HYPERNATREMIA, COVID-19, HYPONATREMIA, CLINICAL trial registries, PNEUMONIA, COMMUNITY-acquired pneumonia
Abstract

Dysnatremia is associated with increased mortality in patients with community-acquired pneumonia. SARS-COV2 (Severe-acute-respiratory syndrome caused by Coronavirus-type 2) pneumonia can be fatal. The aim of this study was to ascertain whether admittance dysnatremia is associated with mortality, sepsis, or intensive therapy (IT) in patients hospitalized with SARS-COV2 pneumonia. This is a retrospective study of the HOPE-COVID-19 registry, with data collected from January 1th through April 31th, 2020. We selected all hospitalized adult patients with RT-PCR-confirmed SARS-COV2 pneumonia and a registered admission serum sodium level (SNa). Patients were classified as hyponatremic (SNa <135 mmol/L), eunatremic (SNa 135–145 mmol/L), or hypernatremic (SNa >145 mmol/L). Multivariable analyses were performed to elucidate independent relationships of admission hyponatremia and hypernatremia, with mortality, sepsis, or IT during hospitalization. Four thousand six hundred sixty-four patients were analyzed, median age 66 (52–77), 58% males. Death occurred in 988 (21.2%) patients, sepsis was diagnosed in 551 (12%) and IT in 838 (18.4%). Hyponatremia was present in 957/4,664 (20.5%) patients, and hypernatremia in 174/4,664 (3.7%). Both hyponatremia and hypernatremia were associated with mortality and sepsis. Only hyponatremia was associated with IT. In conclusion, hyponatremia and hypernatremia at admission are factors independently associated with mortality and sepsis in patients hospitalized with SARS-COV2 pneumonia. Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT04334291 , NCT04334291. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

17. Enterobacter Bacteremia: An Analysis of 50 Episodes

Author

Bouza, Emilio, de la Torre, Manuel García, Erice, Alejo, Loza, Elena, Diaz-Borrego, José María, and Buzón, Luis

Abstract

• During a six-year period, 147 patients had Enterobacter bacteremia (3.8% of the episodes of bacteremia), with an incidence of 1.25 per 1,000 admitted patients. We chose a random group of 50 cases for analysis. The disease was community acquired in 24% of the cases and nosocomially acquired in the remaining 76%. The bacteremia was unimicrobial in 70% and part of a polymicrobial bacteremia in 30%. The species most commonly causing bacteremia was Enterobacter cloacae. Portals of entry, in decreasing order of frequency, were unknown, surgical wound, respiratory tract, and urinary tract. The most common clinical finding was fever (92%). Shock occurred in 30% of the patients, and only two patients had evidence of disseminated intravascular coagulation. Of the Enterobacter isolates, 12% were resistant to gentamicin. Overall mortality was 42%; factors associated with a poor prognosis were inadequacy of antimicrobial chemotherapy, septic shock, type of underlying disease, clinical condition, and requirement of intensive care.(Arch Intern Med 1985;145:1024-1027)

Published
1985
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results